DURHAM, N.C., and BEIJING, China – October 11, 2022 – Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced that it will present new data from two Phase 1 studies evaluating long-acting BRII-778 and BRII-732, both for the treatment of HIV infection, at IDWeek 2022, which will take place in Washington, DC from October 19-23, 2022.

The posters will be available to view via the interactive program site on Wednesday, October 19, 2022 at 8:00am ET. Additional details of the poster presentations are as follows:

Presentation Title: Safety, Tolerability, and Pharmacokinetics of BRII-732, A Medoxomil Carbonate Prodrug of Islatravir in Healthy Adult Subjects [#1282]

Presenter: David Margolis, M.D., MPH, Head of Infectious Diseases Therapy Area at Brii Biosciences

Session Title: HIV: Treatment

Session Date/Time: Friday, October 21, 2022 at 12:15 - 1:30pm ET

Session Location: Walter E. Washington Convention Center in Exhibit Hall BC

Presentation Title: Safety, Tolerability, and Pharmacokinetics of BRII-778, A Modified-Release Oral Formulation of Rilpivirine in Healthy Adult Subjects [#1283]

Presenter: David Margolis, M.D., MPH, Head of Infectious Diseases Therapy Area at Brii Biosciences

Session Title: HIV: Treatment

Session Date/Time: Friday, October 21, 2022 at 12:15 - 1:30pm ET

Session Location: Walter E. Washington Convention Center in Exhibit Hall BC

About BRII-732

BRII-732 is a new chemical entity (NCE) in Phase 1 development that, upon oral administration, is a proprietary prodrug that is metabolized into the active moiety islatravir, an investigational candidate being studied to treat and prevent HIV infection, which functions as both a potent nucleoside reverse transcriptase inhibitor (NRTI) and a nucleoside analogue reverse transcriptase translocation inhibitor (NRTTI). BRII-732 is being developed as part of a once-weekly, combination therapy with BRII-778, which together offer three distinct and comprehensive mechanisms of action – non-nucleoside reverse transcriptase inhibitor (NNRTI), NRTI, and NRTTI – to potentially treat HIV-1 as a complete treatment regimen.

About BRII-778

BRII-778 is in Phase 1 development as an extended-release formulation of rilpivirine hydrochloride, an FDA-approved instant-release non-nucleoside reverse transcriptase inhibitor (NNRTI), which has exhibited antiviral activity against a broad panel of HIV-1 isolates. BRII-778 has been formulated as a modified release oral tablet to enable once-weekly dosing – a potentially preferable choice for patients currently receiving once-daily treatment for HIV. BRII-778 binds to the NNRTI binding site, resulting in conformational changes and altered function of reverse transcriptase. BRII-778 is being developed as part of a once-weekly, combination therapy with BRII-732, which together offer three distinct and comprehensive mechanisms of action – NNRTI, nucleoside reverse transcriptase inhibitors (NRTI), and nucleoside analogue reverse transcriptase translocation inhibitor (NRTTI) – to potentially treat HIV-1 as a complete treatment regimen.

About Brii Bio

Brii Biosciences Limited (“Brii Bio”, stock code: 2137.HK) is a biotechnology company based in China and the United States committed to advancing therapies for significant infectious diseases, such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens worldwide. For more information, visit www.briibio.com.

Media Inquiry:
media@briibio.com
Darcie Robinson (U.S.)
+1-203-919-7905

Investor Inquiry:
ir@briibio.com